3PC-050 Application of hazard vulnerability analysis to evaluate potential risks of pharmacy compounding

Abstract

The compounded product has suitable pharmaceutical characteristics, such as rheology, in vitro release profile and a pH value suitable for oral administration.Its clinical application in a patient with grade 3 mucositis resulted in excellent acceptability and significant reduction in the degree of mucositis (for grade I) and re-introduction of EVR into the therapeutic regimen at the end of a week of treatment with the gel. Conclusion This mucoadhesive gel can be an effective option for the prophylaxis/treatment of oral mucositis, for its prolonged residence time in the oral cavity and easier administration. The pleasant taste promotes a good therapeutic compliance, as well as the smooth and suitable texture for the treatment of an aggressive mucosa. The inclusion of more patients in this study will validate these assumptions. REFERENCE AND/OR ACKNOWLEDGEMENTSRugo HS, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol [Internet]